78554-67-3

Basic information

• Product Name: 4'-Nitrobenzo-12-crown-4
• Synonyms: 4'-Nitrobenzo-12-crown-4
• CAS NO: 78554-67-3
• Molecular Formula: C₁₂H₁₅NO₆
• Molecular Weight: 269.2506
• Mol File: 78554-67-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 108-109 °C(Solv: ethanol (64-17-5))
• Boiling Point: 417.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.231±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4'-Nitrobenzo-12-crown-4(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-Nitrobenzo-12-crown-4(78554-67-3)
• EPA Substance Registry System: 4'-Nitrobenzo-12-crown-4(78554-67-3)

Safety Data

• Hazardous Substances Data: 78554-67-3(Hazardous Substances Data)

Upstream product

• 120-80-9 benzene-1,2-diol 
• 112-26-5 1,2-bis(2-chloroethoxy)ethane 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 19249-03-7 triethylene glycol di-(p-toluenesulfonate) 
• 14174-08-4 benzo-12-crown-4 

Downstream Products

• 511538-52-6 (2-{2-[2-(2-iodo-ethoxy)-ethoxy]-ethoxy}-4-nitro-phenyl)-methyl-amine 
• 511538-49-1 (2-{2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy}-4-nitro-phenyl)-methyl-amine 
• 194923-89-2 2-{2-[2-(2-Methylamino-5-nitro-phenoxy)-ethoxy]-ethoxy}-ethanol 

Relevant articles and documents

THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.

SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF

The invention provide novel pyrimidine derivatives and analogs having inhibitory activities towards certain tyrosine kinases, e.g., Bruton's tyrosine kinase (Btk) and/or Focal adhesion kinase (FAK), extracellular signal-regulated kinase (ERK), pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by such by tyrosine kinases, e.g., cancers, tumors, fibrosis, inflammatory diseases, autoimmune diseases, diabetes, or immunologically mediated diseases.

Two new "onium" fluorosilicates, the products of interaction of fluorosilicic acid with 12-membered macrocycles: Structures and spectroscopic properties

Two novel compounds, (L1H)2[SiF6] ·2H2O (1) and (L2H)2[SiF 5(H2O)]2·3H2O (2), resulting from the reactions of H2SiF6 with 4′-aminobenzo-12- crown-4 (L1) and monoaza-12-crown-4 (L2), respectively, were studied by X-ray diffraction and characterised by IR and 19F NMR spectroscopic methods. Both complexes have ionic structures due to the proton transfer from the fluorosilicic acid to the primary amine group in L1 and secondary amine group incorporated into the macrocycle L2. The structure of 1 is composed of [SiF6]2- centrosymmetric anions, N-protonated cations (L1H)+, and two water molecules, all components being bound in the layer through a system of NH...F, NH...O and OH...F hydrogen bonds. The [SiF 6]2- anions and water molecules are assembled into inorganic negatively-charged layers via OH...F hydrogen bonds. The structure of 2 is a rare example of stabilisation of the complex anion [SiF 5(H2O)]-, the labile product of hydrolytic transformations of the [SiF6]2- anion in an aqueous solution. The components of 2, i.e., [SiF5(H2O)] -, (L2H)+, and water molecules, are linked by a system of NH...F, NH...O, OH...F, OH...O hydrogen bonds. In a way similar to 1, the [SiF5(H2O)]- anions and water molecules in 2 are combined into an inorganic negatively-charged layer through OH...F and OH...O interactions. The Royal Society of Chemistry.